Better Health for All

The company's core business involves providing over-the-counter (OTC) pharmaceutical products and health supplements, which inherently offer health benefits, with no evidence of products causing negative health impacts.

The company enlists its products with the Hong Kong Department of Health, indicating regulatory oversight for safety, and has an adverse events rate of less than 1 per million users. Furthermore, the company provides product information review and pre-consultation services, demonstrating excellent risk transparency.

Kind to Animals

No specific, quantifiable evidence was found in the provided articles to assess HKPD.US against any of the 'Kind to Animals' KPIs. The articles indicate that the company distributes pharmaceutical products that may have been developed using animal testing and may contain animal-derived ingredients, which is the reason for its inclusion on a cruelty-free investing list.

However, this information does not provide concrete data points such as percentages of cruelty-free certified products, animal testing volumes, or investment in animal-free alternatives, which are required by the rubric for scoring.

No War, No Weapons

Hong Kong Pharma Digital Technology Holdings Limited operates in the OTC pharmaceutical e-commerce sector, focusing on supply chain services and procurement/distribution.

The provided articles explicitly state that all metrics related to arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investment, defense-related policies, and other conflict-related activities are 'Not applicable' or 'N/A' for the company's operations. This indicates that the company's core business model does not involve any activities related to war or weapons.

Planet-Friendly Business

The company's total Scope 1, 2, and 3 greenhouse gas emissions for 2024 were 147,836.86 tCO₂e.

While Scope 1 and 2 emissions decreased by 9.15% from 2023 to 2024, Scope 3 emissions were only reported for 2024, preventing a full year-on-year comparison across all scopes. The company has committed to reducing Scope 1 and 2 emissions per unit of revenue by 40% by 2030, using 2021 as the base year, and is actively seeking SBTi validation for these targets. Only 219.12 MWh of total energy consumption in 2024 came from renewable sources. The municipal water withdrawal volume per unit of revenue was 0.17 m³/RMB million in 2024, a reduction from 0.31 m³/RMB million in 2023. The non-hazardous waste recycling rate was 81.75% in 2024, a decrease from 97.15% in 2023. The company is embedding life cycle assessment (LCA) into its R&D processes. Biodiversity assessments have been conducted for major operational sites, covering a 50-kilometer radius. All operating sites complied with environmental protection standards in the reporting period, incurring no penalties. Environmental impact assessments are conducted for newly constructed facilities and equipment. The company has a carbon neutrality target of no later than 2055. It references ISSB IFRS S2 and Stock Exchange Guidelines for climate disclosure and has selected two climate scenarios (high-emission and stringent) for evaluating physical and transition risks. Water-intensive production sites are located in regions with relatively low water resource risk. The company is deploying R&D of long-acting dosage forms to reduce carbon emissions from product packaging and transportation.

Zero Waste & Sustainable Products

The provided articles focus exclusively on HKPD.US's financial performance, including net revenue, gross profit, total expenses, and net income for H1 2024.

All articles explicitly state that no data related to waste management, sustainability, zero-waste initiatives, or any other metrics relevant to the 'Zero Waste & Sustainable Products' value is available. Therefore, no KPIs can be scored based on the evidence provided.